Literature DB >> 33850321

Blood-brain barrier-traversing biologic secures regulatory approval, in Japan.

Asher Mullard.   

Abstract

Year:  2021        PMID： 33850321     DOI： 10.1038/d41573-021-00066-y

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  3 in total

Review 1.  CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success?

Authors:  Pooria Safarzadeh Kozani; Pouya Safarzadeh Kozani; Fatemeh Rahbarizadeh
Journal:  Front Med       Date:  2022-06-10       Impact factor: 9.927

2.  Optimal model establishment of whole-process management data for CAR-T therapy in China-how should this be done?

Authors:  Xiaolei Li; Hanren Dai; Xian Li; Ping Li; Wenbin Qian; Aibin Liang; Weidong Han
Journal:  Cell Mol Immunol       Date:  2021-10-25       Impact factor: 11.530

3.  Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice.

Authors:  Chia-Hung Tsai; Aman P Singh; Cindy Q Xia; Haiqing Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-07-22       Impact factor: 2.410
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.